Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆

Xiaohua Wu(Fudan University Shanghai Cancer Center), Mansoor Raza Mirza(C4 Therapeutics (United States)), L.P. Chen(Guangzhou Medical University), Min Hao(Shanxi Medical University), K. Wang(Tianjin Medical University Cancer Institute and Hospital), Lai Wang(Arog Pharmaceuticals (United States)), Rui An(The Eighth Hospital of Xi'an), C. Zhang, Beihua Kong(Qilu Hospital of Shandong University), Lingying Wu(Chang Gung University), Jianmei Hou, Qingmei Chen(First Affiliated Hospital of Xiamen University), Xianghua Huang(Jiangsu Province Hospital), Xiaojian Yan(Wenzhou Medical University), Yunong Gao, Xusheng Tian, Rutie Yin(Sichuan University), Guangyao Li(Yangtze University), Jihong Liu(Sun Yat-sen University), Yu Zhang(Wannan Medical College), Ge Lou(Harbin Medical University), Xin Lu(Sanofi (United States)), Junke Wang(University of Toronto), Heng Cui(Peking University), Haizhen Yang(Kunming Medical University), Hao Wen(Second Affiliated Hospital of Nanjing Medical University), Qi Zhou(Fudan University), Guzhalinuer Abulizi(Xinjiang Medical University), Z.L. Liu(Jilin University), Jiaqian Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Weiguo Lü(Henan Academy of Agricultural Sciences), Jianqing Zhu, Dongsheng Wang(Liaoning Cancer Hospital & Institute), Yi Huang(Hubei Cancer Hospital)

Annals of Oncology

January 14, 2021

Cited by 212

|Annals of Oncology|2015|1.4k

|Science|2024|1.3k

|Annals of Oncology|2019|1.2k

|International Journal of Gynecological Cancer|2015|757

|Cancer Cell|2007|573

Related Papers